AbbVie registers first-in-human Phase 1 trial for oral ABBV-1162
AbbVie has registered a Phase 1 trial testing single ascending doses of oral ABBV-1162 in healthy adults, not yet recruiting.
AbbVie's registry activity this week centers on a single new early-stage study.
- AbbVie registered "A Phase 1, Double-blind, Placebo-Controlled, First-in-Human Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of ABBV-1162 in Healthy Subjects" (NCT07832708), a Phase 1 trial in healthy volunteers, with status listed as not yet recruiting, with an estimated start date of 2026-11-02 and estimated primary completion in 2027-05.1 The study plans to enroll 40 participants, randomized to receive a single oral dose of either ABBV-1162 or placebo.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.